Presently, the biochemical diagnosis industry is facing fierce competitions in the price, policies, and development models.

In terms of the pharmaceutical macro-political environment, the biomedical industry policies such as medical insurance cost control and target quantity procurement, are gradually implementing.

Anhui Healthcare Security Administration in November issued a notice that a procurement involving 5 product categories and covering 25 provinces starts. The procurement will last 2 years.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On 28 July, NHSA issued the "Notice on Providing Basic Medical Security for Urban and Rural Residents in 2023 by National Healthcare Security Administration, Ministry of Finance and State Taxation Administration".